Kevin Weibel, D.O.
NPI 1104864016 · Hematology & Oncology Physician · Tulsa, OK
Enrolled with Medicare as Practitioner - Hematology/Oncology · source: CMS PECOS Public Provider Enrollment (2026.04.01)
Provider details
- NPI number
- 1104864016
- Entity type
- Individual
- Primary specialty
- Hematology & Oncology PhysicianAllopathic & Osteopathic Physicians
- Credential
- D.O.
- Sex
- Female
- Sole proprietor
- No
- License
- 2559 (OK)
Specialties & taxonomies
Allopathic & Osteopathic Physicians
Profile Score
A profile completeness & documented-activity index — NOT a quality, outcomes, or patient-satisfaction rating.
- Registry tenure25% of score
20 yrs in NPPES registry
- Profile completeness25% of score
100% of core fields populated
- Practice footprint15% of score
1 documented practice location
- Medicare service volume (vs. specialty peers)25% of score
12,877 Medicare services, 2024 (ranked within specialty)
- Open Payments transparency10% of score
Has Open Payments disclosures (2024)
Medicare volume is ranked against active providers in the same specialty. Signals a provider has no public data for (e.g. Medicare claims) are left out of the score entirely — never counted as zero — so providers without that data are not penalized. See the full formula and weights in our .
What this provider does (Medicare)
Based on Medicare fee-for-service claims, 2024; not all care is captured.
| Service (HCPCS) | Medicare services | Typical Medicare-allowed (2024) |
|---|---|---|
| Injection, Fosaprepitant (focinvez), 1 MgJ1434 | 1,652 | $5 |
| Flow Cytometry Technique for Dna Or Cell Analysis, Each Additional Marker88185 | 1,054 | $21 |
| Complete Blood Cell Count (red Cells, White Blood Cell, Platelets), Automated Test and Automated Differential White Blood Cell Count85025 | 852 | $8 |
| Blood Test, Comprehensive Group of Blood Chemicals80053 | 846 | $10 |
| Phosphate Level84100 | 843 | $5 |
| Magnesium Level83735 | 842 | $7 |
| Uric Acid Level, Blood |
What this provider prescribes (Medicare Part D)
Top drugs by Medicare Part D claim volume, 2024 · 31 distinct drugs on file.
| Drug | Part D claims (2024) | Beneficiaries |
|---|---|---|
| Anastrozole | 183 | 48 |
| Letrozole | 148 | 39 |
| Tamoxifen Citrate | 122 | 29 |
| Gabapentin | 62 | 11 |
| Hydrocodone/Acetaminophenbrand: Hydrocodone-Acetaminophen | 59 | 25 |
| Acyclovir | 59 | 12 |
| Ondansetronbrand: Ondansetron Odt | 59 | 41 |
Transparency — industry payments
Based on CMS Open Payments, 2024; not all care is captured.
$1,019 across 36 records (Open Payments 2024)
Open Payments discloses payments and transfers of value (meals, travel, consulting, research, royalties) from drug and device makers to providers. This is a transparency signal, not a verdict — such payments are legal and common, and their presence is neither an endorsement nor a criticism. Source: CMS Open Payments, program year 2024.
Practice location
Mailing address
Registry dates
- Enumerated
- 2006-06-03
- Last updated
- 2014-05-08
Source: CMS NPPES Data Dissemination (June 2026). NPI Central is not affiliated with CMS. Data is provided as-is from the public registry.